Agios Pharm Stock Analysis

Agios Stock Analysis Notes

About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharm recorded a loss per share of 7.12. The entity had not issued any dividends in recent years. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Agios Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 0 people. For more info on Agios Pharm please contact Brian MBA at 617 649 8600 or go to https://www.agios.com.

Agios Pharm Investment Alerts

Agios Largest EPS Surprises

View All Earnings Estimates

Agios Pharm Environmental, Social, and Governance (ESG) Scores

Agios Stock Institutional Investors

Note, although Agios Pharm's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Agios Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.64 B.

Agios Profitablity

Management Efficiency

Agios Pharm has return on total asset (ROA) of (0.1871) % which means that it has lost $0.1871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2922) %, meaning that it created substantial loss on money invested by shareholders. Agios Pharm's management efficiency ratios could be used to measure how well Agios Pharm manages its routine affairs as well as how well it operates its assets and liabilities. As of the 15th of February 2026, Return On Tangible Assets is likely to grow to -0.3. In addition to that, Return On Capital Employed is likely to drop to -0.41. At this time, Agios Pharm's Non Currrent Assets Other are very stable compared to the past year. As of the 15th of February 2026, Other Assets is likely to grow to about 4.8 M, while Total Assets are likely to drop about 869.3 M.

Technical Drivers

As of the 15th of February 2026, Agios Pharm shows the Risk Adjusted Performance of (0.02), mean deviation of 3.09, and Standard Deviation of 7.27. Agios Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Agios Pharm Price Movement Analysis

Agios Pharm Insider Trading Activities

Agios Pharm Outstanding Bonds

Agios Pharm Predictive Daily Indicators

Agios Pharm Corporate Filings

Agios Pharm Forecast Models

Agios Pharm's time-series forecasting models are one of many Agios Pharm's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Agios Pharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Agios Pharm Bond Ratings

Agios Pharm financial ratings play a critical role in determining how much Agios Pharm have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Agios Pharm's borrowing costs.

Agios Pharm Debt to Cash Allocation

Agios Pharm currently holds 40.21 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Agios Pharm has a current ratio of 17.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Agios Pharm's use of debt, we should always consider it together with its cash and equity.

Agios Pharm Total Assets Over Time

Agios Pharm Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Agios Pharm uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Agios Pharm Debt Ratio

2.94

It appears that most of the Agios Pharm's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Agios Pharm's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Agios Pharm, which in turn will lower the firm's financial flexibility.

Agios Pharm Corporate Bonds Issued

Agios Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Agios Pharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Agios shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Agios Pharm. By using and applying Agios Stock analysis, traders can create a robust methodology for identifying Agios entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Agios analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Agios analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Agios Pharm stock analysis indicators help investors evaluate how Agios Pharm stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Agios Pharm shares will generate the highest return on investment. By understating and applying Agios Pharm stock analysis, traders can identify Agios Pharm position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.

Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.